We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
London-based Sparta Biodiscovery has secured up to 3.5 million pounds ($4.3 million) in funding for the commercial rollout of its nanoparticle analyzers, which are used in the development of advanced medicines.